Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact

Archives

Monthly Archive for: "Gennaio, 2023"
Home » Archivi per Gennaio 2023
0

Nouscom announces appointment of Yen-Ching Chua as Vice President of Clinical Operations

We are thrilled to welcome Yen-Ching Chua as VP of Clinical Operations at Nouscom. Yen-Ching is an experienced global clinical operations leader with over 20 years expertise in leading [...]

READ MORE
0

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer

BASEL, Switzerland – 5th January 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into [...]

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!